News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Veloxis Pharmaceuticals A/S (VELO) Announces Positive Two-Year Results From Pivotal Phase 3 Study Of Envarsus® XR (Tacrolimus Extended-Release Tablets) In De Novo Kidney Transplant Patients



6/23/2014 10:50:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that two-year results of the pivotal Phase 3 clinical trial, Study 3002, of Envarsus® XR (tacrolimus extended-release tablets) in de novo kidney transplant patients continued to demonstrate non-inferiority compared to tacrolimus capsules (Prograf®; Astellas Pharma). Data will be presented in a late-breaker session at the World Transplant Congress (WTC) in San Francisco, entitled “Two-Year Results of Envarsus (Once-daily MeltDose Tacrolimus Tablets) vs Prograf (Twice-daily Tacrolimus Capsules): A Phase 3, Double-Blind, Double-Dummy, Multi-Center, Prospective, Randomized Study” at 6:30 p.m. PDT on July 27th.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES